Patent ID: 8663640

Claim:
A method for treatment of cancer in a subject in need thereof that has been subjected to a prior treatment regimen using an anti-human EGFR antibody, said method comprising administering to said subject an antibody composition comprising at least a first anti-human EGFR antibody molecule and a second anti-human EGFR antibody molecule distinct from the first molecule, a. wherein the first anti-human EGFR antibody molecule is selected from the group consisting, (i) an antibody whose light chain comprises amino acids 3-216 of SEQ ID NO:72, and whose heavy chain has a variable domain (VH) comprising amino acids 3-124 of SEQ ID NO:40 and a constant region comprising the amino acid sequence of SEQ ID NO: 91; (ii) an antibody whose light chain has a variable domain (VL) comprising amino acids 3-109 of SEQ ID NO:72 and whose VH comprises amino acids 3-124 of SEQ ID NO:40; and (iii) an antibody having the light chain CDR1, CDR2, and CDR3 in SEQ ID NO: 72 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO: 40; and b. wherein the second anti-human EGFR antibody molecule is selected from the group consisting of (i) an antibody whose light chain comprises amino acids 3-221 of SEQ ID NO:73, and whose heavy chain has a variable domain (VH) comprising amino acids 3-120 of SEQ ID NO:41 and a constant region comprising the amino acid sequence of SEQ ID NO: 91: (ii) an antibody whose VL comprises amino acids 3-114 of SEQ ID NO:73 and whose VH comprises amino acids 3-120 of SEQ ID NO:41; and (iii) an antibody having the light chain CDR1, CDR2, and CDR3 in SEQ ID NO: 73 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO: 41, wherein the prior treatment regimen does not use the first antibody molecule, the second antibody molecule, an antibody molecule have light chain CDR1, CDR2 and CDR3 in SEQ ID NO:74 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO:42, or any combination of these antibody molecules.